Sugammadex: Another milestone in clinical neuromuscular pharmacology

Anesthesia and Analgesia

Volumn 104, Issue 3, 2007, Pages 575-581

  Naguib, Mohamed ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PANCURONIUM; PLACEBO; ROCURONIUM; SUGAMMADEX; SUXAMETHONIUM; TUBOCURARINE CHLORIDE;

ANESTHESIA INDUCTION; ANESTHESIA LEVEL; ANESTHESIA MECHANISM; ANESTHESIST; ANESTHETIC RECOVERY; BISPECTRAL INDEX; BODY MOVEMENT; BODY TEMPERATURE; CAPNOGRAPHY; CLINICAL PHARMACOLOGY; COUGHING; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HYPOTENSION; ISOTHERMAL TITRATION CALORIMETRY; NAUSEA; NEUROMUSCULAR BLOCKING; NONHUMAN; PARALYSIS; PATIENT MONITORING; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PULSE OXIMETRY; QT PROLONGATION; RECEPTOR AFFINITY; RECOVERY ROOM; REVIEW; SIDE EFFECT; SMELLING DISORDER; STRUCTURE ANALYSIS; UNSPECIFIED SIDE EFFECT; VOMITING; XEROSTOMIA;

EID: 33847235862     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000244594.63318.fc     Document Type: Article

References (58)

1. Dale HH. Chemical transmission of the effects of nerve impulses. Br Med J 1934;1:835-41.
2. Dale HH, Feldberg W, Vogt M. Release of acetylcholine at voluntary nerve endings. J Physiol 1936;86:353-80.
3. Läwen A. Über die Verbindung der Lokalanästhesie mit der Narkose, über hohe Extraduralanästhesie und epidurale Injektionen anästhesierender Lösungen bei tabischen Magenkrisen. Beitr klin Chir 1912;80:168-80.
4. Bodman RI, Gillies D. Harold Griffith: The evolution of modern anaesthesia. 1st ed. Toronto: Hannah Institute and Dundurn Press, 1992.
5. Prescott F, Organe G, Rothbotham S. Tubocurarine chloride as an adjunct to anaesthesia. Lancet 1946;2:80-4.
6. Savarese JJ, Kitz RJ. Does clinical anesthesia need new neuromuscular blocking agents? Anesthesiology 1975;42:236-9.
7. Viby-Mogensen J, Jorgensen BC, Ording H. Residual curarization in the recovery room. Anesthesiology 1979;50:539-41.
8. Kim KS, Lew SH, Cho HY, Cheong MA. Residual paralysis induced by either vecuronium or rocuronium after reversal with pyridostigmine. Anesth Analg 2002;95:1656-60.
9. Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology 2003;98:1042-8.
10. Eriksson LI. Reduced hypoxic chemosensitivity in partially paralysed man. A new property of muscle relaxants? Acta Anaesthesiol Scand 1996;40:520-3.
11. Eriksson LI. The effects of residual neuromuscular blockade and volatile anesthetics on the control of ventilation. Anesth Analg 1999;89:243-51.
12. Sorgenfrei IF, Viby-Mogensen J, Swiatek FA. [Does evidence lead to a change in clinical practice? Danish anaesthetists' and nurse anesthetists' clinical practice and knowledge of postoperative residual curarization]. Ugeskr Laeger 2005;167:3878-82.
13. Kopman AF, Yee PS, Neuman GG. Relationship of the train-of-four fade ratio to clinical signs and symptoms of residual paralysis in awake volunteers. Anesthesiology 1997;86:765-71.
14. Eriksson LI. Evidence-based practice and neuromuscular monitoring: it's time for routine quantitative assessment. Anesthesiology 2003;98:1037-9.
15. Bartkowski RR. Incomplete reversal of pancuronium neuromuscular blockade by neostigmine, pyridostigmine, and edrophonium. Anesth Analg 1987;66:594-8.
16. Beemer GH, Bjorksten AR, Dawson PJ, et al. Determinants of the reversal time of competitive neuromuscular block by anticholinesterases. Br J Anaesth 1991;66:469-75.
17. Suresh D, Carter JA, Whitehead JP, et al. Cardiovascular changes at antagonism of atracurium. Effects of different doses of premixed neostigmine and glycopyrronium in a ratio of 5:1. Anaesthesia 1991;46:877-80.
18. Henning RH, Nelemans A, Houwertjes M, Agoston S. Reversal by suramin of neuromuscular block produced by pancuronium in the anaesthetized rat. Br J Pharmacol 1993;108:717-20.
19. Henning RH, Nelemans A, Scaf AH, et al. Suramin reverses non-depolarizing neuromuscular blockade in rat diaphragm. Eur J Pharmacol 1992;216:73-9.
20. Henning RH, Rowan EG, Braga MF, et al. The prejunctional inhibitory effect of suramin on neuromuscular transmission in vitro. Eur J Pharmacol 1996;301:91-7.
21. Kaur M, Reed E, Sartor O, et al. Suramin's development: what did we learn? Invest New Drugs 2002;20:209-19.
22. Naguib M, el-Gammal M, Daoud W, et al. Human plasma cholinesterase for antagonism of prolonged mivacurium-induced neuromuscular blockade. Anesthesiology 1995;82:1288-92.
23. Naguib M, Daoud W, el-Gammal M, et al. Enzymatic antagonism of mivacurium-induced neuromuscular blockade by human plasma cholinesterase. Anesthesiology 1995;83:694-701.
24. Naguib M, Selim M, Bakhamees HS, et al. Enzymatic versus pharmacologic antagonism of profound mivacurium-induced neuromuscular blockade. Anesthesiology 1996;84:1051-9.
25. Belmont MR, Horochiwsky Z, Eliazo RF, Savarese JJ. Reversal of AV430A with cysteine in Rhesus monkeys [abstract]. Anesthesiology 2004;101:A1180.
26. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 2002;41:266-70.
27. Adam JM, Bennett DJ, Bom A, et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem 2002;45:1806-16.
28. Tarver GJ, Grove SJ, Buchanan K, et al. 2-O-substituted cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide. Bioorg Med Chem 2002;10:1819-27.
29. Cameron KS, Clark JK, Cooper A, et al. Modified 4:3403-6.
30. Thompson DO. Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit Rev Ther Drug Carrier Syst 1997;14:1-104.
31. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004;3:1023-35.
32. Munro IC, Newberne PM, Young VR, Bar A. Safety assessment of γ-cyclodextrin. Regul Toxical Pharmacol 2004;39:3-13.
33. Egan TD, Kern SE, Johnson KB, Pace NL. The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic study in a porcine model. Anesth Analg 2003;97:72-9.
34. Baker MT, Naguib M. Propofol: the challenges of formulation. Anesthesiology 2005;103:860-76.
35. Gudmundsdottir H, Sigurjonsdottir JF, Masson M, et al. Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans. Pharmazie 2001;56:963-6.
36. Estebe JP, Ecoffey C, Dollo G, et al. Bupivacaine pharmacokinetics and motor blockade following epidural administration of the bupivacaine- sulphobutylether 7-19:308-10.
37. Meert TF, Mesens J, Verheyen P, Noorduin H. Hydroxypropyl-9:399-409.
38. Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005;103:695-703.
39. Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003;99:632-7.
40. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006;104:667-74.
41. Shields M, Giovannelli M, Mirakhur RK, et al. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 2006;96:36-43.
42. de Boer HD, van Egmond J, van de Pol F, et al. Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: reversal of neuromuscular block in anaesthetized Rhesus monkeys. Br J Anaesth 2006;96:201-6.
43. de Boer HD, van Egmond J, van de Pol F, et al. Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized Rhesus monkeys. Anesthesiology 2006;104:718-23.
44. de Boer HD, van Egmond J, van de Pol F, et al. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. Br J Anaesth 2006;96:473-9.
45. Feldman SA, Tyrrell MF. A new theory of the termination of action of the muscle relaxants. Proc R Soc Med 1970;63:692-5.
46. Bom A, van Egmond J, Hope F, van de Pol F. Rapid reversal of rocuronium-induced neuromuscular block by Org 25969 is independent of renal perfusion [abstract]. Anesthesiology 2003;99:A1158.
47. Paton WD, Waud DR. The margin of safety of neuromuscular transmission. J Physiol 1967;191:59-90.
48. Bom A, Hope F. Neuromuscular block induced by rocuronium and reversed by the encapsulating agent Org 25969 can be re-established using the non-steroidal neuromuscular blockers succinylcholine and cis-atracurium [abstract]. Eur J Anaesthiol 2005;22 (Suppl S34):A457.
49. Kopman AF, Mallhi MU, Neuman GG, Justo MD. Re-establishment of paralysis using mivacurium following apparent full recovery from mivacurium-induced neuromuscular block. Anaesthesia 1996;51:41-4.
50. Naguib M, Abdulatif M, Selim M, al-Ghamdi A. Dose-response studies of the interaction between mivacurium and suxamethonium. Br J Anaesth 1995;74:26-30.
51. Zhang MQ. Drug-specific cyclodextrins: the future of rapid neuromuscular block reversal? Drugs Future 2003;28:347-54.
52. King MJ, Milazkiewicz R, Carli F, Deacock AR. Influence of neostigmine on postoperative vomiting. Br J Anaesth 1988;61:403-6.
53. Kopman AF. Sugammadex: a revolutionary approach to neuromuscular antagonism. Anesthesiology 2006;104:631-3.
54. Philip BK. Practical cost-effective choices: ambulatory general anesthesia. J Clin Anesth 1995;7:606-13.
55. White PF, Watcha MF. Pharmacoeconomics in anaesthesia: what are the issues? Eur J Anaesthesiol Suppl 2001;23:10-15.
56. Souetre EJ, Qing W, Hardens M. Methodological approaches to pharmaco-economics. Fundam Clin Pharmacol 1994;8:101-7.
57. Hayes AH, Breslin DS, Mirakhur RK, et al. Frequency of haemoglobin desaturation with the use of succinylcholine during rapid sequence induction of anaesthesia. Acta Anaesthesiol Scand 2001;45:746-9.
58. Naguib M, Samarkandi AH, Abdullah K, et al. Succinylcholine dosage and apnea-induced hemoglobin desaturation in patients. Anesthesiology 2005;102:35-40.